Poolbeg Pharma PLC has received a Notice of Allowance from the Israeli Patent Office for its POLB 001 drug, designed to prevent cytokine release syndrome (CRS) caused by cancer immunotherapy. This follows patent grants in Europe, Australia, and Canada, strengthening the drug's global intellectual property protection. POLB 001 targets CRS, a serious immune reaction during cancer treatment, using p38 MAPK inhibitors. The approval enhances the drug's commercial appeal as it progresses through clinical development, marking a key step in Poolbeg's strategy to secure full patent rights worldwide.
East West Bancorp is set to report strong Q2 2026 earnings with an expected EPS of $2.61 and revenue of $785.94 million, reflecting an 11.8% revenue increase and 14.5% EPS growth year-over-year. The bank shows robust financial health with expanding d...
AerCap has selected GE Aerospace's GEnx-1B engines to power 15 additional Boeing 787 Dreamliners, reinforcing its position as the largest owner of these aircraft. The GEnx engine is known for its high reliability and long service life, with a 99.98% ...
Crédit Agricole Brie Picardie conducted share buybacks totaling 13,057 shares from July 13 to July 17, 2026, with daily volumes ranging from 1,605 to 5,095 shares. These transactions were carried out under Article 5 of the Market Abuse Regulation (MA...
Northland Securities has increased its price target for Ouster to $60, reflecting a 55.88% upside from the current price. Ouster, a company specializing in digital LiDAR sensors for autonomous vehicles and robotics, aims to reach EBITDA breakeven wit...
Bank of America recently launched its BofA Rewards™ Program, enrolling over 3 million clients in just seven weeks, signaling strong customer interest. Meanwhile, Representative James A. Himes sold Bank of America shares valued between $1,001 and $15,...
